Apatinib induces 3‐hydroxybutyric acid production in the liver of mice by peroxisome proliferator‐activated receptor α activation to aid its antitumor effect

Abstract

Apatinib, an antiangiogenic agent, shows efficient antitumor activity in a broad range of malignancies. Considering tumor is a type of metabolic disease, we investigated the metabolomics changes in serum and tumor after apatinib treatment and the molecular mechanism of characteristic changes associated with its antitumor efficacy. Molecules in serum and tumor tissue were extracted and analyzed by a gas chromatography‐mass spectrometry metabolic platform. Apatinib significantly inhibited e tumor growth and alleviated metabolic rearrangement in both serum and tumor of A549 xenograft mice. Among these endogenous metabolites, 3‐hydroxybutyric acid (3‐HB) was significantly increased in serum, tumor and liver after apatinib treatment. Interestingly, giving exogenous 3‐HB also inhibited tumor growth. Gene expression, dual luciferase reporter gene assay and molecular docking analysis all indicated that apatinib could induce 3‐HB production through the dependent activation of peroxisome proliferator‐activated receptor α (PPARα) and promotion of fatty acid utilization in the liver. Therefore, increased content of 3‐HB induced by PPARα activation in the liver partially contributed to the antitumor effect of apatinib. It may provide clues to another potential mechanism underlying the antitumor effect of apatinib besides its antiangiogenic effect through inhibiting vascular endothelial growth factor receptor 2.

Fenofibrate Exerts Antitumor Effects in Colon Cancer via Regulation of DNMT1 and CDKN2A

“…Several studies have elucidated the antitumor effect of PPARA in various cancers, including breast cancer, prostate cancer, and ovarian cancer [ 32 – 34 ]. Some studies have drawn contradictory conclusions, suggesting that prolonged administration of PPARA agonists might cause hepatocarcinogenesis; however, the detailed mechanism remains unclear [ 35 ]. In the present study, we analyzed the expression levels of PPARs in pancancers and noted that PPARA was expressed at low levels in several types of tumors, including colon cancer.…”

Serum Metabolomic Profiling to Reveal Potential Biomarkers for the Diagnosis of Fatty Liver Hemorrhagic Syndrome in Laying Hens

“…This finding is consistent with the result of non-alcoholic fatty liver disease (NAFLD) patients with steatosis ( Rodríguez-Gallego et al, 2015 ). Feng et al (2019) has shown a similar result that the activation of peroxisome proliferator-activated receptor α (PPAR α) in the liver can promote the utilization of fatty acids and increase the content of 3-hydroxybutyric acid in serum. Therefore, the above results indicate the decrease of fatty acid β oxidation in FLHS laying hens.…”

Guhong Injection Protects Against Apoptosis in Cerebral Ischemia by Maintaining Cerebral Microvasculature and Mitochondrial Integrity Through the PI3K/AKT Pathway

“…There is interplay between VEGF (A, B, C, D, and E) ligands and VEGF receptors (VEGFR-1, 2, and 3) ( Colombo et al, 2018 ). Activation of VEGFR, a member of the receptor tyrosine kinase (RTK) family, will then lead to upregulation of multiple cellular pathways (PI3K/AKT) that promote cell growth and angiogenesis ( Feng et al, 2019 ; Wu et al, 2019 ; Kaufman et al, 2021 ). Transforming growth factor-β1 (TGF-β1) is a polypeptide growth factor that can activate the PI3K/Akt signaling pathway by binding to TβR-I and TβR-II on fibroblasts and other cell membranes and activating receptors ( Li et al, 2012 ; Liu et al, 2019 ).…”